Synthesis 2009(16): 2766-2772  
DOI: 10.1055/s-0029-1216908
PAPER
© Georg Thieme Verlag Stuttgart ˙ New York

Synthesis and Biological Evaluation of 6-Substituted Purinylcarbanucleosides with a Cyclopenta[b]thiophene Pseudosugar

Paula Abeijóna, José M. Blanco*a, Olga Caamañoa, Franco Fernándeza, Marcos D. Garcíab, Xerardo García-Meraa, José E. Rodríguez-Borgesc, Jan Balzarinid, Erik De Clercqd
a Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
Fax: +34(981)594912; e-Mail: jm.blanco@usc.es ;
b Departmento de Química Fundamental, Facultade de Ciencias, Campus da Zapateira s/n, 15701 A Coruña, Spain
c CIQ, Departamento de Química, Facultade de Ciencias do Porto, Rua do Campo Alegre, 687-4169007 Porto, Portugal
d Rega Institute for Medical Research, Katholieke Universiteit Leuven, 3000 Leuven, Belgium
Further Information

Publication History

Received 16 April 2009
Publication Date:
14 July 2009 (online)

Abstract

The first members of a new family of heterocarbobicyclic nucleoside analogues have been synthesized from the cis/trans mixture of (4-amino-5,6-dihydro-4H-cyclopenta[b]thiophen-6-yl)methanols (cis/trans -7). The separation of the cis and trans intermediates during the preparation of the 6-chloropurine derivatives allowed a separate preparation of the purine heterocarbanucleosides cis-10 and trans-11, from which cis-12-14 and trans-16-18 were obtained by replacement of the 6-chloro substituent with amino, hydroxy, and cyclopropylamino groups. Additionally, the 6-phenylpurinyl analogues cis-15 and trans- 19 were prepared from cis-10 and trans-11 using Suzuki-Miyaura methodology. In tests of antiviral and cytostatic activities, compound 11 showed cytostatic activity against Molt4/C8 human T lymphoblastic leukemia cells. Antiviral activity was shown by compounds 15 and 19 against Punta­ Toro virus and Coxackie virus B4 (compound 11).

    References

  • 1a Vermeire K. Schols D. Bell TW. Curr. Med. Chem.  2006,  13:  731 
  • 1b De Clercq E. J. Med. Chem.  2005,  48:  1297 
  • 1c De Clercq E. Front. Med. Chem.  2004,  1:  543 
  • 1d Lazzarin A. Clotet B. Cooper D. Reynes J. Arastéh D. Nelson M. Katlama C. Stellbrink H.-J. Delfraissy J.-F. Lange J. Huson L. DeMasi R. Wat C. Delehanty J. Drobnes C. Salgo M. N. Engl. J. Med.  2003,  348:  2186 
  • 2 Mansour TS. Storer R. Curr. Pharm. Des.  1997,  3:  227 
  • 3a Nucleoside Analogs in Cancer Therapy   Cheson BD. Keating MJ. Plunkett W. Marcel Dekker; New York: 1997. 
  • 3b De Clercq E. Clin. Microb. Rev.  1997,  10:  674 
  • 3c De Clercq E. Curr. Med. Chem.  2001,  8:  1543 
  • 3d Ena J. Pasquau F. Clin. Infect. Dis.  2003,  36:  1186 
  • 3e Louie M. Hogan C. Di Mascio M. Hurley A. Simon V. Rooney J. Ruiz N. Brun S. Sun E. Perelson AS. Ho DD. Markowitz M. J. Infect. Dis.  2003,  187:  896 
  • 4 Balzarini J. Kang G.-J. Dala M. Herdewijn P. De Clercq E. Broker S. Johns DG. Mol. Pharmacol.  1987,  32:  162 
  • 5 Lea AP. Faulds D. Drugs  1996,  51:  846 
  • 6 Krayevsky AA. Watanabe KA. Modified Nucleosides as Anti-AIDS Drugs: Current Status and Perspectives   Bioinform; Moscow: 1993. 
  • 7 Thomas S. McDowall JE. Cheah V. Bye A. Segal MB. The Entry of Abacavir into the Guinea Pig Brain: Comparison with Other Reverse Transcriptase Inhibitors   Presented at the 12th World AIDS Conference, Geneva; Italy: 1998. 
  • For recent reviews of the biological properties of CNs, see:
  • 8a Cho JH. Bernard DL. Sidwell RW. Kern ER. Chu CK. J. Med. Chem.  2006,  49:  1140 
  • 8b Schneller SW. Curr. Top. Med. Chem.  2002,  2:  1087 
  • 8c Rodríguez JB. Comin MJ. Mini Rev. Med. Chem.  2003,  3:  95 
  • 8d Ichicawa E. Kato K. Curr. Med. Chem.  2001,  8:  385 
  • 8e Zhu X.-F. Nucleosides, Nucleotides Nucleic Acids  2000,  19:  651 
  • 8f Agrofoglio L. Challand SR. Acyclic, Carbocyclic and l -Nucleosides   Klewer Academic; Dordrecht: 1998. 
  • 9 Crimmins MT. King BW. J. Org. Chem.  1996,  61:  4192 
  • 10a Foster RH. Faulds D. Drugs  1998,  55:  729 
  • 10b Daluge SM. Martín MT. Sickles BR. Livingston DA. Nucleosides, Nucleotides Nucleic Acids  2000,  19:  297 
  • 10c Mahony WB. Domin BA. Daluge SM. Zimmerman TP. Biochem. Pharmacol.  2004,  68:  1797 
  • 10d Opravil M. Hirschel B. Lazzarin A. Furrer H. Chave J.-P. Yerly S. Bisset LR. Fischer M. Vernazza P. Benasconi E. Battegay M. Ledergerber B. Günthard H. Howe C. Weber R. Perrin L. J. Infect. Dis.  2002,  185:  1251 
  • 11 Bisacchi GS. Chao ST. Bachard C. Daris JP. Innaimo S. Jacobs GA. Kocy O. Lapointe P. Martel A. Merchant Z. Slusarchyk WA. Sundeen JE. Young MG. Colonno R. Zahler R. Bioorg. Med. Chem. Lett.  1997,  7:  127 
  • 12 Wyatt PG. Anslow AS. Coomber BA. Cousins RPC. Evans DN. Gilbert VS. Humber DC. Paternoster IL. Sollis SL. Tapolczay DJ. Weingarten GG. Nucleosides Nucleotides  1995,  14:  2039 
  • 13a Fernández F. García-Mera X. Morales M. Rodríguez-Borges JE. Synthesis  2001,  239 
  • 13b Fernández F. García-Mera X. Morales M. Vilariño L. Caamaño O. De Clercq E. Tetrahedron  2004,  60:  9245 
  • 13c Fernández F. García-Mera X. López C. Morales M. Rodríguez-Borges JE. Synthesis  2005,  3549 
  • 14a Fernández F. García-Mera X. Morales M. Rodríguez-Borges JE. De Clercq E. Synthesis  2002,  1084 
  • 14b Yao S.-W. Lopes VHC. Fernández F. García-Mera X. Morales M. Rodríguez-Borges JE. Cordeiro MNDS. Bioorg. Med. Chem.  2003,  11:  4999 
  • 15 Hocek M. Hol A. Votruba I. Dvoráková H. J. Med. Chem.  2000,  43:  1817 
  • 16a García MD. Caamaño O. Fernández F. Abeijón P. Blanco JM. Synthesis  2006,  73 
  • 16b Caamaño O. Gómez G. Fernández F. García MD. García-Mera X. De Clercq E. Synthesis  2004,  2855 
  • 16c Hergueta AR. López C. García-Mera X. Fernández F. Tetrahedron  2004,  60:  10343 
  • 16d García MD. Caamaño O. Fernández F. Figueira MJ. Gómez G. Synthesis  2003,  2138 
  • 16e López C. Caamaño O. Hergueta AR. García MD. Fernández F. Tetrahedron Lett.  2002,  43:  5311 
  • 17 García MD. Caamaño O. Fernández F. López C. De Clercq E. Synthesis  2005,  925 
  • 18 García MD. Caamaño O. Fernández F. García-Mera X. Pérez-Castro I. Synthesis  2006,  3967 
  • 19a Blanco JM. Caamaño O. Fernández F. Rodríguez-Borges JE. Balzarini J. De Clercq E. Chem. Pharm. Bull.  2003,  51:  1060 
  • 19b Guan H.-P. Ksebati MB. Cheng YC. Drach JC. Kern ER. Zemlicka J. J. Org. Chem.  2000,  65:  1280 
  • 20 Abeijón P. Blanco JM. Fernández F. García MD. López C. Eur. J. Org. Chem.  2006,  759 
  • 21 Yoon NM. Brown HC. J. Am. Chem. Soc.  1968,  90:  2927 
  • 22a Daluge S. Vince R. J. Org. Chem.  1978,  43:  2311 
  • 22b Patil SD. Schneller SW. Hosoya M. Snoeck R. Andrei G. Balzarini J. De Clercq E. J. Med. Chem.  1992,  35:  3372 
  • 24 Cesnek M. Hocek M. Holy A. Collect. Czech. Chem. Commun.  2000,  65:  1357 
  • 25a Hocek M. Eur. J. Org. Chem.  2003,  245 
  • 25b Havelková M. Dvorak D. Hocek M. Synthesis  2001,  1704 
  • 25c Havelková M. Hoces M. Cesnek M. Dovorák D. Synlett  1999,  1145 
  • 26 Suzuki A. J. Organomet. Chem.  1999,  576:  147 ; and references cited therein
  • 27 Walker SD. Barder TE. Martinelli JR. Buchwald SL. Angew. Chem. Int. Ed.  2004,  43:  1871 
  • 28 De Clercq E. In Vitro and Ex Vivo Test Systems to Rationalize Drug Design and Delivery   Cromelin D. Couvreur P. Duchene D. Editions de Sante; Paris: 1994.  p.108 
23

CCDC-636456 contains the supplementary crystallographic data for compound trans-18 reported in this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.